Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.
Kainova Therapeutics has raised $23.5M in total funding. The most recent round was Series B. The last funding was announced in February 2026.
Kainova Therapeutics is headquartered in Illkirch, France.
Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.
Kainova Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kainova Therapeutics — Funding & Investors." VCBacked, February 9, 2026, https://www.vcbacked.co/company/kainova-therapeutics. Accessed August 1, 2026.
VCBacked. (2026). Kainova Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/kainova-therapeutics
{{cite web |title=Kainova Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kainova-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated